Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2894826 | 0.82 | KMT2A (0.56) | KDM4EALDH1A1AKR1C3SMN1; SMN2KMT2A | |
| SCHEMBL14239265 | 0.81 | KDM4E (0.51) | KDM4EKMT2AMEN1CPB2 | |
| SCHEMBL9375743 | 0.81 | KDM4E (0.51) | KDM4EALDH1A1SMN1; SMN2KMT2AMAPT | |
| SCHEMBL27592203 | 0.79 | NOTUM (0.53) | KDM4EALDH1A1SMN1; SMN2KMT2AMAPT | |
| SCHEMBL4424566 | 0.79 | NPC1 (0.53) | KDM4EALDH1A1 | |
| SCHEMBL9375535 | 0.78 | MAPT (0.49) | KDM4EALDH1A1KMT2AMAPTMEN1 | |
| SCHEMBL14167780 | 0.78 | CHRM4 (0.51) | KDM4EALDH1A1 | |
| SCHEMBL27381147 | 0.76 | GRIN2D (0.38) | KDM4EALDH1A1AKR1C3MAPTCPB2 | |
| SCHEMBL9372804 | 0.74 | KDM4E (0.61) | KDM4EALDH1A1SMN1; SMN2KMT2AMAPT | |
| SCHEMBL15578550 | 0.74 | KDM4E (0.53) | KDM4EALDH1A1AKR1C3SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100286211-A1 | OXAZOLIDINONE DERIVATIVES AS ANTIMICROBIALS | RANBAXY LABORATORIES LIMITED (IN) | 2010-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286211-A1 | OXAZOLIDINONE DERIVATIVES AS ANTIMICROBIALS | OXA1L, PDK4, MLYCD | KDM4E 2731/4885ALDH1A1 944/4885AKR1C3 1118/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.